Clinical trial · Observational
Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma
NCT06614205CI-TRIAL-00115864DATUMcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningioma of Brain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tumoral dosimetry by scintigraphy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients treated with 177Lu-DOTATATE for meningioma
- description
- Patients treated with 177Lu-DOTATATE for meningioma at the Nancy's hospital who met the treatment criteria of the Compassionate Prescribing Framework and received a scintigraphy at D1, D4 and D7 (± 1 day)
- interventionNames
- Diagnostic Test: tumoral dosimetry by scintigraphy
Primary outcomes (1)
- measure
- Diagnostic accuracy for progression free survival
- timeFrame
- Day 1
- description
- Accuracy of tumor dosimetry to predict 6-month progression-free survival.
Secondary outcomes (1)
- measure
- Diagnostic accuracy for overal survival
- timeFrame
- Day 1
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients treated for menigioma at nancy hospital * patients who performed 3 scintigraphics exams during there treatment Exclusion Criteria: * patients deprived of liberty * patient who refused to collect data retrospectively
References
Publications (1)
- RESULTBoursier C, Zaragori T, Garabedian N, Blonski M, Obara T, Taillandier L, Imbert L, Verger A. [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. Eur J Nucl Med Mol Imaging. 2026 Feb;53(3):2047-2053. doi: 10.1007/s00259-025-07555-x. Epub 2025 Sep 22. PMID 40982021